September 1st at 1 pm, don’t miss João Frei “When the Brain Sleeps, Microglia Listen: Responses to MCH Neuron Activity” at the A0.02 auditorium in UMinho’s School of Medicine.
|
M
Mon
|
T
Tue
|
W
Wed
|
T
Thu
|
F
Fri
|
S
Sat
|
S
Sun
|
|---|---|---|---|---|---|---|
|
1 event,
-
September 1st at 1 pm, don’t miss João Frei “When the Brain Sleeps, Microglia Listen: Responses to MCH Neuron Activity” at the A0.02 auditorium in UMinho’s School of Medicine. |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
1 event,
-
September 8th at 1 pm, don’t miss Marta Araújo “Elucidation of the Functional Roles of Lipid Metabolism During Leishmaniasis” at the A0.02 auditorium in UMinho’s School of Medicine. |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
1 event,
-
September 15th at 1 pm, don’t miss Tatiana Fernandes “Unravelling the role of itaconate in the immunometabolic regulation of antifungal immunity” at the A0.02 auditorium in UMinho’s School of Medicine. |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
1 event,
-
September 22nd at 1 pm, don’t miss Ana Clara Faria "Cholinergic dynamics of projections from Laterodorsal Tegmentum to the Nucleus Accumbens in associative learning" at the A0.02 auditorium in UMinho’s School of Medicine. |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
1 event,
-
September 29th at 1 pm, don’t miss Mariana Ferreira “Sleep and MCH-neuron impact on microglia-Aβ plaque dynamics” at the A0.02 auditorium in UMinho’s School of Medicine. |
0 events,
|
0 events,
|
1 event,
-
October 2nd at 1 pm, don’t miss Bruno Almeida's "IPLEXMED: Driving the Next Generation of Diagnostics from Lab to Life" at the A0.03 auditorium in UMinho’s School of Medicine. IPLEXMED, a spin-off from the University of Minho and INL, is developing NEXAGUARD®—a portable, graphene-based diagnostic platform delivering lab-quality results in 20 minutes at the point of care or at home. Validated at TRL 6 with multiple patents filed, it targets bacterial respiratory infections and AMR, with plans to expand to STDs, sepsis, and hospital-acquired infections. Market launch is set for 2027 with a scalable “razor-and-blade” model, driving faster diagnostics, improved… |
0 events,
|
0 events,
|
0 events,
|